Latest Industry Insights

Discover how one of the biggest biopharma acquisitions of 2025 aims to expand rare tumor therapies for hard-to-treat cancers like desmoid tumors.

In this article, we explore how AI, robotics and advanced software are transforming biopharma labs, the challenges of adopting these technologies and the vision for the “Lab of the Future.”

In this interview, Dr. Denise Teber, a scientific expert in molecular biology at Charles River Laboratories, discusses how ddPCR is being used to improve contamination risk management.

Explore how onshoring pharmaceutical manufacturing could reshape US drug production and boost supply chain resilience.

In the heart of Cambridge, a quiet revolution is reshaping the way science startups scale: one built not only on breakthrough molecules and patents, but also on collaborative spaces, shared values and pragmatic support.

A recent milestone study used the LNP delivery system developed by Acuitas Therapeutics to treat a newborn with urea cycle disorder (UCD) successfully with a personalized CRISPR therapy. We spoke to Dr. Ying Tam, their CSO, to find out more.

In this opinion piece, Dr. Stella Vnook explores how cell and gene therapy leaders are adapting to today’s financial and regulatory headwinds, offering actionable insights into how biotech CEOs are rethinking capital strategy.

As global scientific and regulatory landscapes shift, companies across the life sciences sector are under growing pressure to adapt. Hear how Phenomenex are taking a proactive approach.

This article explores the unique characteristics and challenges of life sciences marketing, offering insights on how to achieve meaningful engagement with a highly specialized audience.

Explore why cell and gene therapy manufacturing failures are now a leading cause of FDA rejections and how to avoid them.